M. Gail Murphy

Effect of L-000845704, an αVβ3 Integrin Antagonist, on Markers of Bone Turnover and Bone Mineral Density in Postmenopausal Osteoporotic Women

M. Gail Murphy, K. Cerchio, S. Aubrey Stoch et al. · The Journal of Clinical Endocrinology & Metabolism · 2005 · 137 citations · Full text

Medicine, Pharmacotherapy, Bone Augmentation +16

Tolerability of Fosaprepitant and Bioequivalency to Aprepitant in Healthy Subjects

Kenneth C. Lasseter, Jay J. Gambale, Bo Jin et al. · The Journal of Clinical Pharmacology · 2007 · 133 citations

Pharmacy, Pharmacokinetics, Pharmacology +14

Pharmacodynamic and pharmacokinetic effects of MK-0343, a GABA _A α _2,3 subtype selective agonist, compared to lorazepam and placebo in healthy male volunteers

Sanne Lysbet de Haas, Saco J. de Visser, J. P. Van Der Post et al. · Journal of Psychopharmacology · 2007 · 105 citations

Medicine, Pharmacology, Pharmacotherapy +17

MK-677, an Orally Active Growth Hormone Secretagogue, Reverses Diet-Induced Catabolism1

M. Gail Murphy, Laura M. Plunkett, B. J. Gertz et al. · The Journal of Clinical Endocrinology & Metabolism · 1998 · 89 citations · Full text

Agriculture, Endocrinology, Nutritional Sciences +15

Inhibition of capsaicin‐induced increase in dermal blood flow by the oral CGRP receptor antagonist, telcagepant (MK‐0974)

Simon Sinclair, Stefanie A. Kane, Bart Van der Schueren et al. · British Journal of Clinical Pharmacology · 2009 · 87 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17